ERBB2 and breast carcinoma: Trastuzumab was approved for the treatment of metastatic HER2+ breast cancer in Thailand in September 2000.[3] However, as of May 2014, trastuzumab had not been listed on the NLEM.[2,33] Only patients covered by the CSMBS had access the medicine free of charge; SSS and UC enrollees needed to pay out of pocket for trastuzumab treatment.